Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.

Cardiovasc Diabetol · 2017 · PMC5598064 · PMID 28903775

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an adverse trendno p-value reported

There was an adverse trend for hHF in the Study of Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) [ 33 ], but there was no evidence of an increase in hHF risk in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [ 34 ].

also in 93 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.